Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) – Oppenheimer Holdings lowered their Q3 2017 earnings per share estimates for shares of Intercept Pharmaceuticals in a research report issued on Monday. Oppenheimer Holdings analyst J. Olson now forecasts that the biopharmaceutical company will post earnings per share of ($3.49) for the quarter, down from their previous estimate of ($3.17). Oppenheimer Holdings currently has a “Outperform” rating and a $200.00 target price on the stock. Oppenheimer Holdings also issued estimates for Intercept Pharmaceuticals’ Q4 2017 earnings at ($3.19) EPS, FY2017 earnings at ($13.74) EPS, FY2018 earnings at ($8.03) EPS and FY2019 earnings at ($2.39) EPS.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. The company had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 119.17%. Intercept Pharmaceuticals’s revenue for the quarter was up 459.6% on a year-over-year basis. During the same period in the prior year, the business posted ($3.14) earnings per share. COPYRIGHT VIOLATION WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) to Post Q3 2017 Earnings of ($3.49) Per Share, Oppenheimer Holdings Forecasts” was originally reported by BBNS and is owned by of BBNS. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://baseballnewssource.com/markets/intercept-pharmaceuticals-inc-icpt-to-post-q3-2017-earnings-of-3-49-per-share-oppenheimer-holdings-forecasts-updated/1344340.html.
A number of other equities analysts have also recently commented on the stock. Laidlaw reaffirmed a “hold” rating and set a $119.00 price target (up from $115.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday. BMO Capital Markets lifted their price target on shares of Intercept Pharmaceuticals from $218.00 to $221.00 and gave the stock an “outperform” rating in a research note on Tuesday. Wedbush reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday. Cantor Fitzgerald reaffirmed an “underweight” rating and set a $69.00 price target (up from $60.00) on shares of Intercept Pharmaceuticals in a research note on Monday. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $275.00 price target on shares of Intercept Pharmaceuticals in a research note on Sunday. Three analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $196.39.
Shares of Intercept Pharmaceuticals (ICPT) opened at 110.76 on Wednesday. The stock’s market capitalization is $2.77 billion. The stock’s 50 day moving average is $124.94 and its 200-day moving average is $118.29. Intercept Pharmaceuticals has a 12-month low of $96.63 and a 12-month high of $177.93.
Several large investors have recently bought and sold shares of ICPT. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares in the last quarter. US Bancorp DE acquired a new stake in Intercept Pharmaceuticals during the first quarter valued at approximately $130,000. IFP Advisors Inc raised its stake in Intercept Pharmaceuticals by 128.1% in the second quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 730 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Intercept Pharmaceuticals during the first quarter valued at approximately $170,000. Finally, Pacer Advisors Inc. raised its stake in Intercept Pharmaceuticals by 21.6% in the first quarter. Pacer Advisors Inc. now owns 1,861 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 330 shares in the last quarter. Institutional investors and hedge funds own 84.27% of the company’s stock.
In other news, insider Lisa Bright sold 254 shares of the business’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $117.52, for a total value of $29,850.08. Following the completion of the sale, the insider now owns 23,246 shares in the company, valued at approximately $2,731,869.92. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Sandip Kapadia sold 1,431 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $121.59, for a total transaction of $173,995.29. Following the completion of the sale, the chief financial officer now owns 20,569 shares of the company’s stock, valued at approximately $2,500,984.71. The disclosure for this sale can be found here. In the last 90 days, insiders sold 45,583 shares of company stock valued at $5,905,154. Company insiders own 4.50% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.